4D Molecular Therapeutics (FDMT) Interest Coverage Ratio (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Interest Coverage Ratio of 2.81 for Q1 2026, up 92.65% year-over-year from 1.46 in Q1 2025, and down 126.78% quarter-over-quarter from 10.51 in Q4 2025.
4D Molecular Therapeutics (FDMT) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Interest Coverage Ratio for 7 consecutive years, with 2.81 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 92.65% year-over-year to 2.81; the TTM figure through Mar 2026 stood at 6.86 (up 86.83% YoY), while the FY2025 annual figure was 1.01, up 31.39% from the prior year.
- Interest Coverage Ratio eased to 2.81 in Q1 2026 per FDMT's latest filing, from 10.51 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 10.51 in Q4 2025 and bottomed at 62.35 in Q4 2024.
- Historically, Interest Coverage Ratio has averaged 13.65 across 5 years, with a median of 2.81 in 2026.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio sank 3084.7% — and 2025, when it soared 116.86%.
- 4D Molecular Therapeutics' Interest Coverage Ratio stood at 9.9 in 2022, then plunged by 362.62% to 45.82 in 2023, then slumped by 36.1% to 62.35 in 2024, then surged by 116.86% to 10.51 in 2025, then tumbled by 126.78% to 2.81 in 2026.
- Business Quant data shows FDMT's Interest Coverage Ratio at 2.81 in Q1 2026, 10.51 in Q4 2025, and 2.11 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -3.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.12 |
| Mar 31, 2026 | -2.81 |
| Dec 31, 2025 | 10.51 |
| Sep 30, 2025 | -2.11 |
| Jun 30, 2025 | -1.95 |
| Mar 31, 2025 | -38.30 |
| Dec 31, 2024 | -62.35 |
| Sep 30, 2024 | -1.50 |
| Jun 30, 2024 | -15.11 |
| Mar 31, 2024 | -47.67 |
| Dec 31, 2023 | -45.82 |
| Sep 30, 2023 | -0.74 |
| Jun 30, 2023 | -1.63 |
| Mar 31, 2023 | -1.50 |
| Dec 31, 2022 | -9.90 |
| Sep 30, 2022 | -1.23 |
| Jun 30, 2022 | -5.27 |
| Mar 31, 2022 | -4.60 |
| Dec 31, 2021 | -20.64 |
| Sep 30, 2021 | -0.90 |